相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.
Sara Lonardi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients
Kristine O. Aasebo et al.
CANCER MEDICINE (2019)
Validation of diagnosis codes to identify side of colon in an electronic health record registry
Patricia Luhn et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer
Jason Timothy Henry et al.
CHINESE CLINICAL ONCOLOGY (2019)
NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults
Talha Shaikh et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S. Stintzing et al.
EUROPEAN JOURNAL OF CANCER (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Sabine Tejpar et al.
JAMA ONCOLOGY (2017)
Analysis of factors influencing molecular testing at diagnostic of colorectal cancer
Quentin Thiebault et al.
BMC CANCER (2017)
Social disparities in survival after diagnosis with colorectal cancer: Contribution of race and insurance status
Dianne Pulte et al.
CANCER EPIDEMIOLOGY (2017)
Differences in Colorectal Cancer Outcomes by Race and Insurance
Rima Tawk et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2016)
Chemotherapy Use and Adoption of New Agents Is Affected by Age and Comorbidities in Patients With Metastatic Colorectal Cancer
Namrata Vijayvergia et al.
CANCER (2016)
Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Patterns of Use and Tolerance of Anti-Epidermal Growth Factor Receptor Antibodies in Older Adults With Metastatic Colorectal Cancer
Efrat Dotan et al.
CLINICAL COLORECTAL CANCER (2014)
Refining the Chemotherapy Approach for Older Patients With Colon Cancer
Nadine J. McCleary et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Drugging the undruggable RAS: Mission Possible?
Adrienne D. Cox et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Challenges in the Management of Older Patients With Colon Cancer
Efrat Dotan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
Clinical Practice Guidelines in Oncology
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives
GENETICS IN MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Molecular Characterization of MSI-H Colorectal Cancer by MLH1 Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening
Jenny N. Poynter et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer
Salvatore Artale et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Referral to medical oncology: A crucial step in the treatment of older patients with stage III colon cancer
RuiLi Luo et al.
ONCOLOGIST (2006)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Frequency of loss of hMLH1 expression in colorectal carcinoma increases with advancing age
S Kakar et al.
CANCER (2003)
Genomic medicine - Hereditary colorectal cancer
HT Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
